Drug Profile


Alternative Names: HOE-239

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hoechst Pharma
  • Developer Drugs for Neglected Diseases Initiative Foundation; Sanofi
  • Class Antiparasitics; Nitroimidazoles
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Trypanosomiasis
  • Phase II Chagas disease; Visceral leishmaniasis

Most Recent Events

  • 04 Nov 2017 Drugs for Neglected Disease initiative completes a phase III trial in Trypanosomiasis (In adolescents, In adults, In the elderly) in Democratic Republic of the Congo and Central African Republic (PO) (NCT03025789)
  • 13 Sep 2017 Phase-II clinical trials in Chagas' disease in Spain (PO) (EudraCT2016-004905-15)
  • 10 Jul 2017 Drugs for neglected disease initiative foundation announces intention to submit a MAA/regulatory dossier to EMA under Article 58 for Trypanosomiasis in late 2017 (Drugs for neglected disease initiative foundation pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top